Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial

View Full Paper
Ask AI
Bookmark
Share

Authors

ADAlexey V. DanilovTMTalha MunirAAAlvaro J. Alencar

Discussion

Loading...

Member takes

Overview

Phase 1 trial reports rapid, durable efficacy of bexobrutideg in relapsed/refractory chronic lymphocytic leukemia, suggesting it may overcome BTK resistance.

Key Points

  • Evaluate the efficacy and safety of bexobrutideg in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
  • Conducted a Phase 1 trial with dose-escalation and randomized cohorts.
  • Evaluated safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) profile.
  • Included patients with a median of 4 prior therapy lines.
  • 230 patients enrolled, with significant responses observed in relapsed/refractory CLL.
  • Overall response rate (ORR) was 78.6% among evaluable patients.
  • Bexobrutideg was well tolerated with no dose-limiting toxicities reported.

Cite This Study

Danilov et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d031https://doi.org/10.1182/blood-2025-86
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in patients with Waldenström macroglobulinemia: Updated results from an ongoing Phase 1a/b study2025 · 2 citations
  2. 2Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor2025 · 2 citations
  3. 3Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study2025 · 1 citations
  4. 4CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma2025 · 1 citations
  5. 5Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study2025 · 1 citations